GENERAL COMMENTS
The main aim of this paper was to explore gender differences in prescribing practices for acute coronary syndromes (ACS) and to evaluate whether ACS patients in Barbados were treated with optimal medical therapy in both the hospital and community settings. The authors state that in Barbados, unpublished data indicates that in-hospital acute MI case-fatality rate (2013) was 40.8% with higher rates in women after age-adjustment (risk ratio=1.18; 95% CI 1.02-1.37) . The authors however do not give any data concerning death rates in their study population . From Figure 1 we can argue that among 1589 patients admitted for MI ( STEMI or NSTEMI ) 1295 had data abstracted from hospital notes (with 114 having a diagnosis confirmed by autopsy ) and 294 had a diagnosis from a death certificate . The mortality rate for patients arriving alive to hospitals for MI is arguably ( 294+114)/1589 = 31.5% . Unfortunately the authors do not mention the mortality rates for men and women . The data presented concern physicians prescriptions during hospitalization and at discharge . An analysis of factors related to non adherence to guidelines recommendations ( beyond gender ) should be performed . No patients were apparently treated invasively , even though in Table 1 about 10 per cent of patients had undergone coronary angiography in their medical history . This is likely the greatest failure in the health system in Barbados . The authors should comment on this and should specify if organization has changed in the latest years.
The clinical variables associated with MI patients look interesting : obesity was present in a range between 70% and 89% of patients , diabetes from 55% to 82% and atrial fibrillation rate was rather high ( from 26% to 35% of all patients ) considering that mean age was globally below 70 years . Only age was adjusted as confounders, whereas there were other potential confounders which need to be adjusted to get an unbiased estimate. That's my only concern and would recommend doing the analyses again considering all the potential confounders.
3. There should be analyses for younger and older women to examine difference in outcomes and discussion should explain the effects of hormones in this relation. Reviewer stated: The authors however do not give any data concerning death rates in their study population. From Figure 1 we can argue that among 1589 patients admitted for MI (STEMI or NSTEMI ) 1295 had data abstracted from hospital notes (with 114 having a diagnosis confirmed by autopsy ) and 294 had a diagnosis from a death certificate . The mortality rate for patients arriving alive to hospitals for MI is arguably (294+114)/1589 = 31.5%. Unfortunately, the authors do not mention the mortality rates for men and women.
VERSION 1 -AUTHOR RESPONSE
I assumed that the reviewer was referring to the ischaemic heart disease cause-specific mortality for men and women. At line 80 I have inserted the age-standardised mortality rate due to MI for both sexes according to the Barbados National Registry but no sex differential given. This data was also not available in the Ministry of Health's last published annual report which was 2012.
An analysis of factors related to nonadherence to guidelines recommendations (beyond gender) should be performed.
In response to this suggestion, we performed univariate analyses of co-morbidities available in the dataset on adherence to fibrinolysis only. We also included the results of the logistic regression model that best described the factors affecting adherence to fibrinolysis. These references have been added to line 278.
Data analyses section did not explain how adjustment was done. Only age was adjusted as confounders, whereas there were other potential confounders which need to be adjusted to get an unbiased estimate. That's my only concern and would recommend doing the analyses again considering all the potential confounders.
Adjustment of age was described at lines 182 -183 in the first manuscript. We didn't initially adjust for co-morbidities since, of the factors listed in the hospital protocol as absolute contraindications for fibrinolysis only one was adequately collected by the registry -systolic blood pressure on admission.
Since reviewer one appeared to be asking for other factors related to non-adherence to fibrinolytics we conducted univariate and multivariable analyses exploring the associations between several available comorbidities (hypertension, diabetes, previous ischaemic heart disease, obesity, smoking, history of coronary angiography, atrial fibrillation, congestive cardiac failure and systolic blood pressure on presentation). Additional analyses are described at lines 186-192.
There should be analyses for younger and older women to examine difference in outcomes and discussion should explain the effects of hormones in this relation.
This analysis was attempted and numbers within groups were too small in this population to yield meaningful logistic regression results when adjustments were made for potential confounders as suggested above. 
